Clinical Trial Update: Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and tolerability of sacubitril/valsartan in patients with Heart Failure with reduced ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: National Institute of Cardiovascular Diseases, Pakistan | Conditions: Heart Failure, Systolic | Phase 4 | Status: COMPLETED